Targeting aurora kinases limits tumour growth through DNA damage‐mediated senescence and blockade of NF‐κB impairs this drug‐induced senescence
Year: 2012
Type: article
Abstract: Oncogene-induced senescence can provide a protective mechanism against tumour progression. However, production of cytokines and growth factors by senescent cells may contribute to tumour development. Thus, it is unclear whether induction of senescence represents a viable therapeutic approach. Here, using a mouse model with orthotopic implantation of metastatic melanoma tumours taken from 19 patients, we observed that targeting aurora kinases with MLN8054/MLN8237 impaired mitosis, induced senescence and markedly blocked proliferation in patient tumour implants. Importantly, when a subset of tumour-bearing mice were monitored for tumour progression after pausing MLN8054 treatment, 50% of the tumours did not progress over a 12-month period. Mechanistic analyses revealed that inhibition of aurora kinases induced polyploidy and the ATM/Chk2 DNA damage response, which mediated senescence and a NF-κB-related, senescence-associated secretory phenotype (SASP). Blockade of IKKβ/NF-κB led to reversal of MLN8237-induced senescence and SASP. Results demonstrate that removal of senescent tumour cells by infiltrating myeloid cells is crucial for inhibition of tumour re-growth. Altogether, these data demonstrate that induction of senescence, coupled with immune surveillance, can limit melanoma growth.
Source: EMBO Molecular Medicine
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $7,990
Funders: U.S. Department of Veterans Affairs, National Institutes of Health, U.S. Food and Drug Administration, U.S. Public Health Service, Vanderbilt Digestive Diseases Research Center, Vanderbilt University Medical Center, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences
Awards: G1188393146, G153582612, G1621550296, G1764958080, G236830079, G359867969, G4818761672, G4991472964, G5471862801, G72294304, The Vanderbilt Institute for Clinical and Translational Research (VICTR), Inst.Research and Academic Career Development Award, Vanderbilt Clinical Oncology Research Career Development Award, Molecular and Cellular Basis for Digestive Diseases, Integrated Biological Systems Training in Oncology, Cancer Center Support Grant, (2/3) MMC, VICC, and TSU: Partners in Eliminating Cancer Disparities
OpenAlex ID: W1959572016
